(Q57990927)

Paolo Santiago Ocampo

2

0 references

Nicolas Coudray

Nicolas Coudray

1

0 references

Aristotelis Tsirigos

Aristotelis Tsirigos

9

0 references

Matija Snuderl

Matija Snuderl

5

0 references

author name string

Theodore Sakellaropoulos

3

0 references

Navneet Narula

4

0 references

David Fenyö

6

0 references

Andre L. Moreira

describes a project that uses

7

0 references

language of work or name

English

0 references

publication date

17 September 2018

0 references

published in

Nature Medicine

0 references

volume

24

0 references

issue

10

0 references

page(s)

1559-1567

0 references

1 reference

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Current status of targeted therapy in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Prognostic and predictive biomarkers in lung cancer. A review

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Accuracy of classifying poorly differentiated non-small cell lung carcinoma biopsies with commonly used lung carcinoma markers.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Comprehensive Computational Pathological Image Analysis Predicts Lung Cancer Prognosis

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Predicting non-small cell lung cancer prognosis by fully automated microscopic pathology image features

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Deep Convolutional Neural Networks Enable Discrimination of Heterogeneous Digital Pathology Images

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Quantification of free circulating DNA as a diagnostic marker in lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Deep learning in neural networks: an overview

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Guest Editorial Deep Learning in Medical Imaging: Overview and Future Promise of an Exciting New Technique

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Deep Learning in Medical Image Analysis

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

An Automatic Learning-Based Framework for Robust Nucleus Segmentation.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Multi-radial LBP Features as a Tool for Rapid Glomerular Detection and Assessment in Whole Slide Histopathology Images.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Computer-Aided Diagnosis with Deep Learning Architecture: Applications to Breast Lesions in US Images and Pulmonary Nodules in CT Scans

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Accurate and reproducible invasive breast cancer detection in whole-slide images: A Deep Learning approach for quantifying tumor extent

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Locality Sensitive Deep Learning for Detection and Classification of Nuclei in Routine Colon Cancer Histology Images.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Lung Pattern Classification for Interstitial Lung Diseases Using a Deep Convolutional Neural Network

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Going deeper with convolutions

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Dermatologist-level classification of skin cancer with deep neural networks

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Development and Validation of a Deep Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus Photographs

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Toward a Shared Vision for Cancer Genomic Data

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Current State of the Regulatory Trajectory for Whole Slide Imaging Devices in the USA.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Role of LKB1 in lung cancer development

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

TP53 mutations in nonsmall cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Mutational landscape and significance across 12 major cancer types

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Laser capture microdissection: molecular analysis of tissue

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Correlation between morphology and EGFR mutations in lung adenocarcinomas Significance of the micropapillary pattern and the hobnail cell type

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

LKB1 tumor suppressor protein: PARtaker in cell polarity

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Changes in p53 expression can modify cell shape of ras-transformed fibroblasts and epitheliocytes.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

EGFR mutation is specific for terminal respiratory unit type adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Comprehensive histologic analysis of ALK-rearranged lung carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap).

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Standardization of epidermal growth factor receptor (EGFR) measurement by quantitative immunofluorescence and impact on antibody-based mutation detection in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

A systems pathology model for predicting overall survival in patients with refractory, advanced non-small-cell lung cancer treated with gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Comprehensive genomic characterization of squamous cell lung cancers

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

Comprehensive molecular profiling of lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

The meaning and use of the area under a receiver operating characteristic (ROC) curve

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021

A Coefficient of Agreement for Nominal Scales

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0177-5

7 January 2021